Table 1.

Summary of the concentration-dependent effects of acute and subchronic administrations of CLZ, QTP and BPZ on astroglial l-glutamate release and Cx43 expression in the plasma membrane.

	Administration	CLZ	QTP	BPZ	Figure
Astroglial glutamate release
Basal glutamate release	Acute (120 min)	↑	→	→	Figure 1
	Subchronic (7 days)	→	→	→	Figure 1
Evoked glutamate release	Acute (120 min)	↑↑	↑	↑	Figure 2
	Subchronic (7 days)	↑↑	↑↑	↑↑	Figure 3
Evoked release	Acute (120 min)	↑↑	↑↑	↑↑	Figure 2
(+subchronic VPA)	Subchronic (7 days)	↑↑	↑↑	↑↑	Figure 3
Akt inhibitor sensitivity of glutamate release
Evoked release	Acute (120 min)	↓	→	→	Figure 5
(+ subchronic VPA)	Subchronic (7 days)	↓	↓	→	Figure 5
Cx43 expression in the astroglial plasma membrane
(+ subchronic VPA)	Acute (120 min)	↑↑	→	→	Figure 7
(+ subchronic VPA)	Subchronic (7 days)	↑↑	↑↑	↑↑	Figure 7
Akt sensitivity of Cx43 expression in the astroglial plasma membrane
(+ subchronic VPA)	Acute (120 min)	↓↓	→	→	Figure 7
(+ subchronic VPA)	Subchronic (7 days)	↓↓	↓↓	→	Figure 7

→: no effect, ↑: increased by supratherapeutic concentration but unaffected by therapeutic-relevant concentration, ↑↑: increased by therapeutic-relevant concentration.